Background and aims: Tumour-infiltrating lymphocytes (TILs) in breast cancer (BC) provide prognostic and predictive information. The aim of this study was to assess the spatial and temporal heterogeneity of TILs in BC and its relationship with immune cell subtypes. Methods and results: Immunohistochemically defined immune cell subtypes, i.e. those expressing T-cell markers (CD3, CD8, and FOXP3), a B-cell marker (CD20) and a histiocytic marker (CD68), were evaluated in a large series (n = 1165) of invasive BCs. A subset of full-face haematoxylin and eosin (H&E)-stained slides were examined for TILs heterogeneity within primary tumours and the corresponding local recurrent carcinomas to investigate spatial and temporal TILs heterogeneity. H&E-stained sections from multiple tumour blocks (three or four blocks per case) representing different tumour areas were evaluated to assess TILs interslide heterogeneity and intraslide heterogeneity. Both average stromal TILs (AV-TILs) and hotspot stromal TILs (HS-TILs) were assessed.
Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance
Background and aims: Tumour-infiltrating lymphocytes (TILs) in breast cancer (BC) provide prognostic and predictive information. The aim of this study was to assess the spatial and temporal heterogeneity of TILs in BC and its relationship with immune cell subtypes. Methods and results: Immunohistochemically defined immune cell subtypes, i.e. those expressing T-cell markers (CD3, CD8, and FOXP3), a B-cell marker (CD20) and a histiocytic marker (CD68), were evaluated in a large series (n = 1165) of invasive BCs. A subset of full-face haematoxylin and eosin (H&E)-stained slides were examined for TILs heterogeneity within primary tumours and the corresponding local recurrent carcinomas to investigate spatial and temporal TILs heterogeneity. H&E-stained sections from multiple tumour blocks (three or four blocks per case) representing different tumour areas were evaluated to assess TILs interslide heterogeneity and intraslide heterogeneity. Both average stromal TILs (AV-TILs) and hotspot stromal TILs (HS-TILs) were assessed.
AV-TILs showed associations with all immune cell subtypes; however, CD3+ cells constituted the main component (mean number of CD3+ was 55), whereas CD20+ cells constituted the smallest component (mean number of CD20 was 13). There was no significant statistical difference between TILs across tumour blocks of the same case (P = 0.251 for AVTILs and P = 0.162 for HS-TILs). Triple-negative breast cancer (TNBC) showed higher TILs percentage than other BC subtypes (P < 0.001). High AV-TILs, CD3+ cells, CD8+ cells and CD20+ cells were associated with longer survival in TNBC patients (P < 0.05). High AV-TILs in recurrent tumours showed a significant association with shorter post
Introduction
The breast cancer (BC) microenvironment comprises a complex mixture of cell types, including immunemodulating cells that provide an opportunity for therapeutic modulation. 1, 2 Several studies have reported prognostic and predictive roles of tumourinfiltrating lymphocytes (TILs) in BC as assessed on haematoxylin and eosin (H&E)-stained sections regardless of their cellular subtypes, [3] [4] [5] [6] and guideline recommendations to standardise TILs assessment in BC have been published. 7 However, the impact of TILs heterogeneity, with variable TILs density and components in different tumour areas within BC subtypes, remains to be defined. Various TILs subtypes have different roles in tumour progression, either suppressing tumour growth by destroying cancer cells, or promoting tumour progression by selecting those tumour cells that could survive in an immunocompetent host. [8] [9] [10] For instance, T lymphocytes, which account for the majority of TILs in invasive BC, can activate host defence mechanisms, 9 mainly through cytotoxic CD8+ T cells. However, T regulatory cells (Tregs) play a vital role in immune tolerance to tumour cells, and can protect against tumour development and progression. [10] [11] [12] The contribution of each immune cell subtype to the prognostic value of overall TILs assessed on H&E-stained slides also remains unclear. In addition, the role of histiocytes, as a component of the immune cells in BC, and whether they contribute prognostic value and should be included in TILs assessment in BC have not been resolved.
The aims of this study were: (i) to investigate the TILs infiltrate in invasive BC and its spatial distribution, and relate this to prognostic parameters and patient outcome in primary and recurrent tumours; and (ii) to investigate the contributions of various immune cell subtypes, as molecularly defined, to overall TILs and their prognostic value.
Materials and methods

S T U D Y C O H O R T
The study cohort comprised 1165 invasive BCs derived from the retrospective Nottingham Primary Breast Carcinoma Series of patients presenting to Nottingham City Hospital between 1988 and 1998. Immunohistochemical detection of a panel of T-lymphocyte markers, including pan-T-cell CD3, cytotoxic T-cell CD8, Treg FOXP3, B-cell CD20, and the histiocytic cell marker CD68, had been previously performed. [13] [14] [15] Full-face H&E-stained sections from a subset of cases (n = 230) were used to assess TILs infiltration and intraslide heterogeneity. Moreover, to assess interslide TILs heterogeneity, H&E-stained slides from multiple formalin-fixed paraffin-embedded archival tissue blocks (three or four blocks per case) were prepared from a subgroup of cases (n = 52/ 230). Patient clinical and pathological data, including age at presentation, histological tumour type, primary tumour size, axillary lymph node status, histological tumour type, Nottingham Prognostic Index (NPI), lymphovascular invasion (LVI), and adjuvant chemotherapy, were available. Biological data on the expression of oestrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), androgen receptor (AR) and basal cytokeratins (CKs), i.e. CK5/6 and CK14, were also available. 16, 17 The data on HER2 were already available for this early-stage BC cohort, and details of staining and scoring were included in previous publications. [18] [19] [20] [21] Survival data were previously retrieved and updated, including: (i) BC-specific survival (BCSS), defined as the time (in months) from the date of primary surgical treatment to the time of death from BC; and (ii) distant metastasis-free survival (DMFS), defined as the time from the surgery until the first distant metastasis. In this study, post-recurrence survival was defined as the time (in months) from the date of surgical removal of the recurrent tumour to the date of death from BC. Of the recurrent cases, 44 patients had local recurrence tumour tissue available, and these were used to compare the TILs distribution between the primary and the corresponding recurrent tumour.
This study was approved by Nottingham Research Ethics Committee 2 under the title 'Development of a molecular genetic classification of breast cancer'.
The total numbers of each immune cell type were counted in the stroma surrounding the tumour in each core. Table S1 shows the details of the different antibodies used.
T I L A S S E S S M E N T O N H & E -S T A I N E D S E C T I O N S
All tumour specimens were routinely fixed in 10% formalin and embedded in paraffin. Full-face, 4-lm sections were prepared for H&E staining, and evaluated for stromal TILs. All cases contained an adequate tumour burden, constituting at least 40% of the section surface area in each slide. H&E-stained slides were scanned into high-resolution digital images at 920 magnification with a 3D Histech Panoramic 250 Flash II scanner (3DHISTECH, Budapest, Hungary). The digital images were viewed with the 3DHISTECH Panoramic Viewer (3DHISTECH). TILs were semiquantitatively assessed according to the recommended method of the 2014 International TILs Working Group. 7 Each section was first scanned at low magnification. The percentage of stromal TILs within the invasive tumor boundaries was estimated. TILs contact tumour cells directly (intra-tumoral) were not accounted in the scoring. Moreover, TILs around crush artefacts, tumour necrosis, extensive central regressive hyalinisation or ductal carcinoma in situ/normal lobules were not considered for quantification. All mononuclear cells, lymphocytes, histiocytic cells, and plasma cells, if any, were scored and recorded as a percentage of TILs. The quantity of TILs was evaluated as the percentage of TILs present in the stroma [average TILs (AV-TILs)]. For further quantification of the pattern of TILs infiltrate, area with the highest number of lymphocytes aggregate was determined and designated as hotspot TILs (HSTILs).HS-TILs was equal to AV-TILs only in the cases showing no or occasional scattered lymphocytes or in rare cases showing dense lymphocytic infiltration throughout the tumour. The area with the highest TILs density was considered to be the hotspot, and was introduced to study both intraslide and interslide TILs heterogeneity. For assessment of intraslide heterogeneity, annotation of each digital image was performed by dividing the tumour area into four quadrants with a vertical line and horizontal line. AV-TILs and HS-TILs were assessed in each quadrant separately in addition to the whole slide. All cases were scored independently by two observers (M.A. and C.J.) blinded to histopathological data and patient outcomes. The observers were trained by a consultant pathologist (E.R.). Also, to test the intraobserver reproducibility of our scoring system, 50% of the cases were randomly selected and rescored by the same scorer.
S T A T I S T I C A L A N A L Y S I S
Intraobserver agreement was determined by use of the Pearson correlation coefficient, and interobserver agreement was determined by use of an intraclass correlation coefficient. TILs scores were categorised with a 10% cut-off; cases with scores of <10% were defined as negative/low, and cases with scores of ≥10% were defined as positive/high. 4 In recurrent tumours, the median percentage of TILs scores (5%) was used. Positive immunoreactivity for CD3, CD8, CD20, FOXP3 and CD68 was defined as previously described. [13] [14] [15] 22 The associations between the categorical groups of TILs density and clinicopathological parameters were analysed with the chi-square test. The Spearman rank correlation coefficient was used to assess the relationship between TILs and immune cell subtypes. The Friedman and Kendall test was used to test TILs expression between four slides (interslide heterogeneity) and in four quadrants (intraslide heterogeneity). The association with patient outcome was assessed with Kaplan-Meier and log-rank tests. Cox proportional hazards regression models were used for multivariate survival analyses to estimate the hazard ratio (HR) of TILs and immune cell subtypes adjusted by other established prognostic factors. A P-value of <0.05 (two-tailed) was considered to be significant in all statistical tests.
Results
I M M U N E C E L L S U B T Y P E S A N D T I L S
In the study cohort, 74.7% of the tumours were ER+, 59% were PgR+, and 9.3% were HER2+. To assess specific subpopulation of TILs, the expression of the lymphocytic biomarkers CD3, CD8, CD20 and FOXP3 and the macrophage/histiocytic biomarker CD68 was evaluated in the whole cohort (n = 1165). Table S2 shows the distribution of immune subtypes within different BC molecular classes. This revealed that the T-lymphocyte population, as demonstrated by pan-T (CD3+ cells), was the main component of TILs, followed by macrophages (CD68+ cells), whereas the B-lymphocyte population (CD20+ cells) was the smallest component. Among T-lymphocytes, the overall contribution of CD8+ cells was more frequent than that of FOXP3+ cells. Despite the increased number of all immune cell components in triple-negative breast cancer (TNBC) compared to other molecular classes, the ratio of each immune cell subtype within each molecular class as well as the whole series appeared similar. The CD3+ cell population was the main contributory component (Figure 1) .
Univariate survival analysis demonstrated that high FOXP3+ and CD68+ counts were associated with shorter BCSS for all BC subtypes (P = 0.006 and P < 0.001, respectively; Figure S1 ). However, high CD20+ cell counts showed a tendency to be associated with longer BCSS (P = 0.066).
A high-CD3+ cell (P = 0.021, P = 0.011), high-CD8+ cell (P = 0.017, P = 0.012) and high-CD20+ cell (P = 0.037, P = 0.045) infiltrate was associated with longer BCSS and DMFS, respectively, in TNBC ( Figure S2A-C) . Dense histiocytic CD68+ cells were associated with shorter BCSS in luminal B tumours (P = 0.04). A high-CD20+ cell infiltrate was associated with better BCSS in HER2+ tumours (P = 0.04) ( Figure S3A,B) . Cox proportional models including patient age, tumour grade, nodal stage and different immune cell subtypes showed that only high-CD8+ cell [P = 0.002, HR 0.5, 95% confidence interval (CI) 0.3-0.8] and high-CD3+ cell (P = 0.003, HR 0.3, 95% CI 0.2-0.7) lymphocytic infiltrates were independent predictors of improved outcome in TNBC, whereas CD20+, CD68+ and FOXP3+ cells were not significantly associated with outcome (Table S3) .
We observed high reproducibility of TILs scoring by the same observer (Pearson correlation coefficients of 0.93 for AV-TILs and 0.97 for HS-TILs), and between the two observers (intraclass correlation coefficients of 0.79 for AV-TILs and 0.83 for HS-TILs, and kappa agreement of 0.825 for AV-TILs and 0.785 for HSTILs), according to the methodology adopted in this study. 7 Interobserver agreement was determined according to the intraclass correlation coefficient for the four slides between the two scorers (0.771 for slide 1, 0.580 for slide 2, 0.682 for slide 3, and 0.910 for slide 4).
The mean, median and range of TILs percentages of average and hotspot scores in both the primary and recurrent tumours are shown in Table S4A,B. No significant differences between slides representing various tumour blocks/areas were identified (interslide variation, P = 0.251 for AV-TILs and P = 0.162 for HS-TILs) ( Figure S4 ). Moreover, our results showed that patients with the luminal A tumours were more homogeneous with respect to interslide AV-TILs expression than other subtypes. When each slide was divided into four quadrants and each quadrant was scored independently, the variation of TILs was statistically significant (intraslide variation, P = 0.019 for AV-TILs and P < 0.0001 for HS-TILs). Interestingly, recurrent tumours showed a trend towards lower TILs scores (P = 0.052) and showed homogeneous TILs distribution as compared with their corresponding primary tumour (Figure 2 ). AV-TILs was higher in TNBC than in other BC classes (P < 0.001). Significant multiple correlations between AV-TILs and different immune cell subpopulations and between the immune cell markers were identified (all P < 0.001).
Tumour-infiltrating lymphocytes (average and hotspot) in primary BC were positively associated with higher tumour grade (P < 0.001), tumour stages (P = 0.038), poor NPI prognostic group (P < 0.001), TNBC (P < 0.001), and AR-negative phenotypes (P = 0.012). No significant association between TILs and patient age, tumour size, lymph node stage or LVI status was identified (Table 1) . TILs (average and hotspot) showed a positive association with grade in TNBC. Interestingly, in TNBC, AR positivity was associated with lower TILs scores (P < 0.001). No association was identified between TILs scores and a basal-like phenotype as defined by basal CK and EGFR expression. 17 Univariate survival analysis showed no significant association between TILs (average and hotspot) and patient BCSS either in the whole cohort or in those with local recurrence. High AV-TILs showed a significant association with longer BCSS in TNBC patients (P = 0.026), as distant metastasis developed in only 91 of 230 cases. However, 61 cases of TNBC showed TILs to be associated with longer DMFS (P = 0.017) (Figure 3 ). This was not observed in other BC subtypes. Notably, survival analysis between treated and untreated patients (chemotherapy and endocrine therapy) did not show a significant association. However, in TNBC, AV-TILs was a prognostic factor independent of adjuvant chemotherapy treatment. No significant association between HS-TILs and BCSS or DMFS was identified in any of the BC subtypes.
As AV-TILs was a significant predictor of outcome in TNBC, further analyses were limited to TNBC. Cox proportional models including other prognostic parameters, i.e. patient age, tumour grade, and nodal stage, showed that AV-TILs was an independent predictor of a good prognosis (P = 0.004, HR 0.4, 95% CI 0.2-0.8). In the model including TILs and various immune cells (CD3+, CD8+, FOXP3+, CD20+, and CD68+), only AV-TILs showed a significant association with patient outcome (Table S5) .
The prognostic power of the combination of positive/negative TILs with high/low immune biomarker expression was investigated; however, there was no significant association in any BC subtype. Interestingly, in recurrent tumours, there was a significant association between high AV-TILs density and shorter post-recurrence patient survival (P = 0.004) (Figure 4) .
Discussion
There is a growing interest in quantifying and reporting total TILs in BC and their different subpopulations in clinical practice, owing to their prognostic and possibly predictive value for immunotherapies. 23, 24 In this study, a large cohort with long-term clinical follow-up was used to assess the expression pattern of different immune cell subtypes in BC as well as their association with patient outcome and tumour progression.
The International TILs Working Group has reported that, in most tumours, there is no obvious interslide heterogeneity (i.e. between multiple tissue sections from different tumour blocks of the same case) in TILs content at the morphological level. However, no robust evidence to support this observational statement has yet been provided. 7 To our knowledge, ours is the first study to assess TILs heterogeneity by utilising multiple tumour tissue blocks from the same primary tumour and comparing these with their corresponding recurrences. For each sample in this study, TILs were assessed as average (AV-TILs) and hotspots (HS-TILs) to elaborate on TILs distributions in different tumour areas. Our results showed no significant differences in overall TILs scores between tumour blocks whether assessed as AV-TILs or HS-TILs, indicating that any full-face H&E-stained breast tumour tissue section is sufficient to evaluate TILs density within a whole tumour. However, when the analysis was limited to smaller tumour areas, i.e. different areas of the same slide (intraslide heterogeneity), the differences in TILs scores were significant, particularly with regard to hotspots. The latter finding represents the presence of substantial intraslide heterogeneity, and therefore underscores the variable nature of immune infiltrates within different tumour cell populations. This is consistent with earlier reports, in which CD8+, CD3+ and CD20+ TILs subpopulations in core biopsies were more heterogeneous across the core than in multiple cores from the same tumour. 25 The variation in CD3+, CD8+ and CD20+ TILs was 30-33% between the core biopsies from the same tumour, whereas a higher variation of 66-69% was present in the same section. 26 Another study reported that spatial heterogeneity of TILs subtypes could play role in patient outcomes. For instance, a high number of CD3+ T lymphocytes in the invasive margin is associated with disease-free survival in BC, where high total and distance CD8+ T lymphocyte corresponded with better outcome in BC. 27 TILs assessed with both methods, i.e. AV-TILs and HS-TILs, were significantly associated with other prognostic parameters in the whole cohort. 27 Interestingly, TILs showed lower proportions and were more homogeneously distributed in recurrent tumours than in their corresponding primary tumours. This is consistent with a previous report in which lower expression of TILs in metastatic recurrences of TNBC and HER2+ BC were observed than in primary tumours. 28 Moreover, significantly shorter post-recurrence survival was observed in patients with recurrences with dense TILs, providing evidence that assessment of TILs in recurrent tumours can be used as a prognostic variable to predict post-recurrence outcome. It is of note that the recurrent tumours included all BC subtypes. Thus, the inverse association could be explained, at least in part, by the heterogeneity of BC and the variation of TILs interactions with primary and recurrent tumours, as well the different subtypes.
This study has shown that TILs subpopulations are differently expressed in BC tumours in which T cells, as defined by CD3+ cells, appeared to dominate. This H&E, haematoxylin and eosin; HER2, human epidermal growth factor receptor 2. *Nodal status is based on the Nottingham system nodal stage (1 for node-negative, 2 for 1-3 positive nodes, and 3 for ≥4 positive nodes). indicates that TILs constitute a heterogeneous mixture of different immune cell types that are most likely recruited to the tumour vicinity to perform specific functions. 29, 30 Additionally, our data showed that CD3+, CD8+, FOXP3+, CD20+ and CD68+ cells were positively correlated with AV-TILs percentage, and that TILs were higher in the more aggressive TNBC subtype than in other subtypes. It has been reported that TILs assessed in H&E-stained sections are significantly correlated with CD20 and CD45 positivity in BC. 31 The high-CD8+ and high-CD3+ cellular infiltrate showed good prognostic and independent predictive value in TNBC regardless of other clinicopathological parameters. These findings are concordant with the results reported by other studies. 15, 32, 33 The higher CD20+ lymphocytes within the tumour were associated with better outcome in TNBC and HER2+ BC. This may point to the higher immunogenicity of TNBC and HER2+ BC than of luminal BC, owing to the production of more B-cell antibodies against the tumour cell, results that are consistent with those reported by Buisseret et al. 34 TNBC was furtherly classified into several subtypes with different clinical relevance in terms of patient outcome and treatment responses. 35 However, there was no significant association between FOXP3+ cells and patient outcome in TNBC. In contrast to our observations, Yeong et al. reported that a high density of intratumoral FOXP3+ cells was associated with longer overall survival but not with stromal infiltration. 36 In our study, lower TILs scores were observed in the AR+ subclass of TNBC, which is considered to be a prime candidate for anti-androgen and CDK4/6 inhibition therapies. 37, 38 However, no differential expression of TILs or various immune cell subtypes was observed with regard to subclassification of TNBC into basal-like and non-basal-like groups. 17 High expression of CD68 was significantly associated with worse outcome in patients with luminal B tumours, which may explain, at least in part, the distinct roles of TILs subpopulations in different BC subtypes. 39 These results also underscore distinct tumour-stromal interactions in TNBC as compared with non-TNBC tumours, as indicated by their different inflammatory microenvironments.
Two types of tumour association macrophage are described, classically activated (M1) and alternatively activated (M2). The latter is associated with growth, angiogenesis, migration and invasion of a diversity of cancers. 40 The significant correlation of AV-TILs with different lymphocyte subtypes and its independent association with outcome regardless other clinicopathological parameters or immune cell subtypes signify the reliability of AV-TILs as assessed on H&E-stained sections for accurate immune cell scoring and provides a robust prognostic value in BC, particularly TNBC. Although CD3+ and CD8+ lymphocytes showed prognostic significance with outcome independent of other clinicopathological parameters, they showed a nonsignificant association with outcome when they were analysed with AV-TILs and other immune cell subtypes.
In conclusion, TILs infiltrates are significantly different between TNBC and non-TNBC, with distinct subpopulations of immune cells being present in the former. This might explain the different prognostic utilities of the TILs infiltrate and the immune cell subtypes in BC. Although the International TILs International Working Group has recognised heterogeneity as an issue, no data are available to provide any strong guidance. Our findings confirm that average TILs assessment on one representative tumour block can provide reliable information on the TILs infiltrate across an entire breast tumour Assessment of the average TILs score by the use of H&E-stained slides provides reproducible and independent prognostic value in TNBC which is more robust than using different immune cell subpopulations. The role of B lymphocytes and histiocytes in BC biology and prognosis, and the association between TILs and outcome in the recurrent tumour, warrant further investigation. 
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Additional Supporting Information may be found in the online version of this article: Figure S1 . Kaplan-Meier survival plots showing associations between FOXP3+ (A) and CD68+ (B) with breast cancer-specific survival (BCSS). Figure S2a . Kaplan-Meier survival plots showing associations between CD3+ lymphocyte density in triple-negative breast cancer and (A) breast cancerspecific survival (BCSS) and (B) distant metastasis-free survival (DMFS). Figure S2b . Kaplan-Meier survival plots showing associations between CD8+ lymphocyte density in triple-negative breast cancer and (A) breast cancerspecific survival (BCSS) and (B) distant metastasis-free survival (DMFS). Figure S2c . Kaplan-Meier survival plots showing associations between CD20+ lymphocyte density in triple-negative breast cancer and (A) breast cancerspecific survival (BCSS) and (B) distant metastasis-free survival (DMFS). Figure S3 . Kaplan-Meier survival plots showing associations between: (A) CD68+ histiocyte in luminal B breast cancer subtype and, (B) CD20+ lymphocyte in HER2+-enriched subtype, with breast cancerspecific survival (BCSS). Figure S4 . Average tumour-infiltrating lymphocyte (TIL) and hotspot TIL scores in multiple tumour blocks. S1, S2, S3 and S4 are sections 1, 2, 3 and 4 from four different tumour blocks. Table S1 . Antibodies used in immunohistochemistry. Table S2 . Mean, median and range of immune cell subtype counts/core diameter assessed as absolute number of cells [in the whole series and in different breast cancer (BC) molecular subtypes]. Table S3 . A multivariate Cox regression hazard model including other prognostic clinicopathological parameters shows that average tumour-infiltrating lymphocytes (TILs) as well as immunohistochemically defined CD3+ or CD8+ T lymphocytes provided an independent prognostic value, being associated with longer breast cancerspecific survival in the subset of triple-negative breast cancer. Table S4A . Mean, median and range of percentage of tumour-infiltrating lymphocytes (TILs) in the primary and corresponding recurrence in a subset of the study cohort (n = 44). Table S4B . Mean, median and range of percentage of tumour-infiltrating lymphocytes (TILs) in different breast cancer molecular subtypes. Table S5 . A multivariate Cox regression hazard model including average tumour-infiltrating lymphocytes (TILs) and various immunohistochemically defined immune cell subtypes shows that average TILs is the only independent prognostic parameter associated with longer breast cancer-specific survival in the subset of triple-negative breast cancers.
